OS Therapies Clarifies CUSIP of Common Stock
OS Therapies (NYSE American: OSTX), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, has issued a clarification regarding the CUSIP identifier of its common stock. The company's stock began trading on the NYSE American on August 1st, 2024, under CUSIP 68764Y108. On August 5th, due to a pre-listing corporate action, a new CUSIP 68764Y207 was assigned. All shares under the old CUSIP are now identified under the new CUSIP, with no share splits or similar actions occurring between August 1-5, 2024. OS Therapies urges all market participants, especially brokerage firms, to update their records accordingly.
OS Therapies (NYSE American: OSTX), un'azienda biopharmaceutica in fase di ricerca e clinica, specializzata in ADC e immunoterapia, ha emesso un chiarimento riguardo l'identificatore CUSIP delle sue azioni ordinarie. Le azioni della società hanno iniziato a essere scambiate sulla NYSE American il 1° agosto 2024, sotto CUSIP 68764Y108. Il 5 agosto, a causa di un'azione aziendale pre-listing, è stato assegnato un nuovo CUSIP 68764Y207. Tutte le azioni sotto il vecchio CUSIP sono ora identificate con il nuovo CUSIP, senza che si siano verificate scissioni azionarie o azioni simili tra il 1 e il 5 agosto 2024. OS Therapies sollecita tutti i partecipanti al mercato, in particolare le società di intermediazione, ad aggiornare di conseguenza i propri registri.
OS Therapies (NYSE American: OSTX), una empresa biofarmacéutica en fase de investigación y clínica, especializada en ADC e inmunoterapia, ha emitido una aclaración sobre el identificador CUSIP de sus acciones ordinarias. Las acciones de la compañía comenzaron a cotizar en NYSE American el 1 de agosto de 2024, bajo CUSIP 68764Y108. El 5 de agosto, debido a una acción corporativa previa a la cotización, se asignó un nuevo CUSIP 68764Y207. Todas las acciones bajo el antiguo CUSIP ahora están identificadas con el nuevo CUSIP, sin que se hayan producido divisiones de acciones ni acciones similares entre el 1 y el 5 de agosto de 2024. OS Therapies insta a todos los participantes del mercado, especialmente a las firmas de corretaje, a actualizar sus registros en consecuencia.
OS Therapies (NYSE American: OSTX)는 ADC 및 면역 요법 연구 및 임상 단계의 생명 공학 회사로, 일반 주식의 CUSIP 식별자에 대한 설명을 발표했습니다. 회사의 주식은 2024년 8월 1일 NYSE American에서 CUSIP 68764Y108으로 거래를 시작했습니다. 8월 5일, 상장 전 기업 행동으로 인해 새로운 CUSIP 68764Y207이 할당되었습니다. 구 CUSIP에 따라 모든 주식은 이제 신규 CUSIP으로 식별됩니다, 2024년 8월 1일부터 5일 사이에 주식 분할 또는 유사한 조치가 발생하지 않았습니다. OS Therapies는 모든 시장 참가자, 특히 중개 회사에 기록을 적절히 업데이트할 것을 촉구하고 있습니다.
OS Therapies (NYSE American: OSTX), une société biopharmaceutique en phase de recherche et clinique spécialisée dans les ADC et l'immunothérapie, a émis une clarification concernant l'identifiant CUSIP de ses actions ordinaires. Les actions de la société ont commencé à être négociées sur NYSE American le 1er août 2024, sous CUSIP 68764Y108. Le 5 août, en raison d'une action d'entreprise préalable à la cotation, un nouveau CUSIP 68764Y207 a été attribué. Toutes les actions sous l'ancien CUSIP sont désormais identifiées sous le nouveau CUSIP, sans que des divisions d'actions ou des actions similaires ne se soient produites entre le 1er et le 5 août 2024. OS Therapies demande à tous les participants au marché, en particulier aux sociétés de courtage, de mettre à jour leurs dossiers en conséquence.
OS Therapies (NYSE American: OSTX), ein biopharmazeutisches Unternehmen in der Forschungs- und Klinikphase, das sich auf ADC und Immuntherapie spezialisiert hat, hat eine Klarstellung zum CUSIP-Identifikator seiner Stammaktien herausgegeben. Die Aktien des Unternehmens begannen am 1. August 2024 an der NYSE American zu handeln, unter CUSIP 68764Y108. Am 5. August wurde aufgrund einer Unternehmensmaßnahme vor der Notierung ein neuer CUSIP 68764Y207 zugewiesen. Alle Aktien unter dem alten CUSIP sind jetzt unter dem neuen CUSIP identifiziert, ohne dass zwischen dem 1. und 5. August 2024 Aktienaufspaltungen oder ähnliche Maßnahmen erfolgt sind. OS Therapies fordert alle Marktteilnehmer, insbesondere Brokerfirmen, auf, ihre Aufzeichnungen entsprechend zu aktualisieren.
- Successful listing on NYSE American exchange on August 1st, 2024
- None.
The Company’s common stock began trading on the NYSE American on August 1st, 2024 under CUSIP 68764Y108 (“Old CUSIP”). On August 5th, the Company completed certain matters related to a corporate action that had occurred prior to the listing of the Company’s common stock on the NYSE American that resulted in new CUSIP 68764Y207 (“New CUSIP”) being assigned to the Company’s common stock. All shares sold or purchased under the Old CUSIP are now identified as the same number of shares under the New CUSIP. No share splits or any other similar actions occurred between August 1, 2024 and August 5, 2024.
All market participants, including brokerage firms, are hereby notified to update their records such that shares of the Company’s common stock listed under the Old CUSIP should be identified, sold and purchased under the New CUSIP 68764Y207.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing strong preclinical efficacy data in various models of breast cancer. In addition, OS Therapies is advancing its next generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company’s proprietary silicone linker technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240822905132/en/
Corporate and Media Contact:
Jack Doll
410-297-7793
Irpr@ostherapies.com
Investor Relations:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
OSTX@redchip.com
Source: OS Therapies
FAQ
What is the new CUSIP for OS Therapies (OSTX) stock?
When did OS Therapies (OSTX) begin trading on the NYSE American?
Did OS Therapies (OSTX) undergo a share split between August 1-5, 2024?
What should brokerage firms do regarding OS Therapies (OSTX) stock?
